LYRA
Lyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.20
+0.00%Latest reported
- Last report date
- Nov 12, 2025
- EPS actual
- -$3.38
- EPS estimate
- -$5.98
- Revenue actual
- $25.0K
- Revenue estimate
- $205.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +10.0%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 12, 2025 | -$5.98 | -$3.38 | Beat 43.48% | $25.0K |
| Aug 12, 2025 | -$5.79 | -$5.51 | Beat 4.84% | $183.0K |
| Mar 13, 2025 | -$0.13 | -$0.16 | Miss -23.08% | $209.0K |
| Aug 14, 2024 | -$0.34 | -$0.29 | Beat 14.71% | $598.0K |
| Mar 21, 2024 | -$0.33 | -$0.22 | Beat 33.33% | $146.0K |
| May 12, 2023 | -$0.36 | -$0.44 | Miss -22.22% | $410.0K |
| Mar 9, 2022 | -$0.82 | -$1.05 | Miss -28.05% | $271.0K |
| Mar 9, 2021 | -$0.61 | -$0.46 | Beat 24.59% | — |
| Nov 10, 2020 | -$0.48 | -$0.49 | Miss -2.08% | — |
| Aug 5, 2020 | -$0.37 | -$0.56 | Miss -51.35% | — |
| May 28, 2020 | — | -$19 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 4, 2026